Bromelain is a glycoprotein that contains a single carbohydrate moiety group and displays proteolytic activity. Bromelain has long been known to act as an immunomodulator; however, the immunomodulatory activity of its carbohydrate moiety has been very rarely studied and is not well understood. This study aimed to predict the immunomodulatory activity of the carbohydrate moiety of bromelain (CMB) by evaluating it using the PASS server, and the binding affinities between CMB and various pro-inflammatory cytokines were analyzed using a molecular docking approach. This research was conducted by docking the CMB ligand to the following receptor proteins: interleukin-6 (IL-6), IκBβ/nuclear factor (NF)-κB p65 homodimer complex (IκBα/NF-κB p65), tumor necrosis factor-alpha (TNF-α), and IL-1β. The biological potential of CMB was predicted using the online PASS server. The results of the computational analysis indicated that the highest binding energy was identified between CMB and IκBβ/NF-κB p65 (−10.3 kcal/mol), followed by TNF-α (−9.7 kcal/mol), and IL-6 and IL-1β, with values of −8.2 kcal/mol for both. The CMB activity predicted by the Way2Drug PASS server indicated that this molecule is likely to display significant immunostimulant activity. These findings suggested that CMB can be considered a potential lead molecule for further drug development to identify agent that can prevent or cure inflammation and restore balance to the immune system. However, the predictions determined in this study remain to be validated in future in vitro and in vivo studies. [ABSTRACT FROM AUTHOR]